Given the genetic and molecular heterogeneity of NSCLC, including the variability of PTEN/PI3K signaling status, further validation across diverse NSCLC cell lines and patient-derived xenograft models is warranted. This evidence concerns the gene PTEN and non-small cell lung carcinoma.